← Human Trials & Peer-Reviewed Studies
Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis
Plain-language guide to PMID 10912846 (2000): randomized controlled trial study of Teriparatide and Parathyroid Hormone (PTH 1-84), osteoporosis and bone density.
Key Facts
- PMID
- 10912846
- Journal
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- Year
- 2000
- Study type
- Randomized Controlled Trial
- Authors
- Lane NE et al. (5 authors)
- DOI
- 10.1007/s001980070111
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide and Parathyroid Hormone (PTH 1-84) in the context of osteoporosis and bone density, published as a randomized controlled trial.
The purpose of this study was to test the ability of early changes in markers of bone turnover to predict subsequent changes in bone mineral density (BMD) induced by parathyroid hormone fragment, PTH (1-34), in postmenopausal osteoporotic women treated with estrogen and glucocorticoids.
Why It Was Studied
Serum and urine were collected at baseline and 1, 3, 6, 9, 12, 18 and 24 months for measurement of bone alkaline phosphatase (BAP), osteocalcin (OC) and deoxypyridinoline (DPD).
The researchers constructed an Uncoupling Index (UI) from all three markers (UI = [ZBAP + Zoc]/2 -ZDPD, where the Z-score for each marker in each subject was calculated from the mean and standard deviation of the study population at baseline).
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, women only.
How the Study Was Run
The design is described as randomized.
Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
BMD of the lumbar spine and hip was measured at baseline and every 6 months thereafter by dual-energy X-ray absorptiometry (DXA) and annually by quantitative computed tomography (QCT; spine only).
What Was Measured
Serum and urine were collected at baseline and 1, 3, 6, 9, 12, 18 and 24 months for measurement of bone alkaline phosphatase (BAP), osteocalcin (OC) and deoxypyridinoline (DPD).
The researchers constructed an Uncoupling Index (UI) from all three markers (UI = [ZBAP + Zoc]/2 -ZDPD, where the Z-score for each marker in each subject was calculated from the mean and standard deviation of the study population at baseline).
PubMed files the paper under topics including Biomarkers, Bone Density, Bone and Bones, Estrogen Replacement Therapy, Glucocorticoids, Osteoporosis, Postmenopausal and ROC Curve.
Author keywords: Non-programmatic.
What This Means in Plain Language
The paper is a randomized study of Teriparatide and Parathyroid Hormone (PTH 1-84) in people with osteoporosis and bone density.
The publication is from 2000 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.
More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, Osteoporosis and bone density research.
Our Notes on the Compounds
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
- Osteoporosis and bone density research
- Teriparatide in the library
- Parathyroid Hormone (PTH 1-84) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.